Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity

v3.20.2
Stockholders' Equity
6 Months Ended
Jun. 30, 2020
Stockholders' equity:  
Stockholders' Equity
7. Stockholders’ Equity

 

2019 Private Placement

 

On May 9, 2019, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Investors”) for the private placement of 2,426,455 shares of the Company’s common stock at $3.10 per share. The Company received aggregate gross proceeds of approximately $7.5 million, before deducting offering expenses aggregating approximately $94,000.

 

The Purchase Agreement also contains representations and warranties by the Company and the Investors and covenants of the Company and the Investors (including indemnification from the Company in the event of breaches of its representations and warranties), certain information rights and other rights, obligations and restrictions, which the Company believes are customary for transactions of this type.

 

Issuance of Common Stock in Lieu of Cash Payments

 

Under the terms of the Amended and Restated Non-Employee Director Compensation Plan, each compensated non-employee member of the Company’s Board of Directors may elect to receive all or part of his or her director fees in shares of the Company’s common stock. Director fees, whether paid in cash or in shares of common stock, are payable quarterly on the last day of each fiscal quarter. The number of shares of common stock issued to directors is determined by dividing the product of: (i)(a) the fees otherwise payable to each director in cash, times (b) the percentage of fees the director elected to receive in shares of common stock, by (ii) the volume weighted average price per share of common stock over the last five trading days of the quarter. The following is information regarding the number of shares issued to directors as payment for director fees in lieu of cash for the three and six months ended June 30, 2020 and 2019:

 

Three Months Ended June 30,
2020   2019  
9,832   8,841  

 

Six Months Ended June 30,  
2020     2019  
  19,563       17,739  

 

Stock Incentive Plans

 

The Company has various share-based compensation plans and share-based compensatory contracts (collectively, the “Plans”) under which it has granted share-based awards, such as stock grants, and incentive and non-qualified stock options, to employees, directors, consultants and advisors. Awards may be subject to a vesting schedule as set forth in individual award agreements. Certain of the Plans also have provided for cash-based performance bonus awards.

 

From October 2017 until June 2020, the Company granted share-based awards under the Company’s Second Amended and Restated 2013 Incentive Compensation Plan (the “Second Amended Plan”). On June 2, 2020, the Company’s stockholders approved the Company’s Third Amended and Restated 2013 Incentive Compensation Plan (the “Third Amended Plan” and, together with the Second Amended Plan, the “2013 Plan”), under which 1 million shares of the Company’s common stock were made available for future issuances under the 2013 Plan, resulting in a total of 2,956,250 shares of the Company’s common stock being reserved for issuance under the 2013 Plan. Of this amount, stock grants of 440,995 shares have been awarded and option grants, net of options terminated, expired or forfeited, of 1,175,679 shares were outstanding as of June 30, 2020. Accordingly, 1,339,576 shares remained available for grants under the 2013 Plan as of that date.

 

Stock option activity under all of the Company’s Plans during the six months ended June 30, 2020 is summarized below:

 

    Shares     Weighted-average
Exercise price
per share
   

Intrinsic
Value(1)

 
Outstanding at January 1, 2020     1,639,167     $ 9.87     $ 2,892,027  
Granted     84,445       4.14       26,512  
Exercised     (833 )     1.74          
Outstanding at June 30, 2020     1,722,779     $ 9.59     $ 867,568  

 

(1) Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.

 

As of June 30, 2020, there was unrecognized compensation expense of $948,807 related to outstanding stock options and shares of restricted stock, which is expected to be recognized over a weighted average period of 1.44 years.

 

Warrants

 

Warrants have generally been issued in connection with financing transactions and for terms of up to five years. Common stock warrant activity for the six months ended June 30, 2020 was as follows:

 

    Shares     Weighted-average
Exercise price
per share
   

Intrinsic
Value(1)

 
Outstanding at January 1, 2020     5,532,267     $ 4.00     $ 10,470,008  
Exercised     (428,532 )     2.20          
Outstanding at June 30, 2020     5,103,735     $ 4.15     $ 2,717,201  

 

(1) Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.